Editorial: Stem cell oversight board is flying blind
By Sacramento Bee,
Sacramento Bee
| 09. 18. 2005
Robert Klein II, the self-appointed czar of California's stem cell institute, has created a completely unworkable system for dispensing $3 billion in taxpayer-funded research grants.
In fact, it is hard to imagine a system that is more convoluted and opaque than what Klein has created. Its shortcomings were on full display at a Sept. 9 meeting of the institute's oversight board here in Sacramento.
At the meeting, the 29-person board (with a few members absent) labored to decide which universities and research entities should receive the institute's first training grants, totalling about $13 million per year.
During the meeting, the distinguished scientists on the panel resembled ballerinas in Kurt Vonnegut's story, "Harrison Bergeron," who tried to dance with bag weights. The scientists didn't have the information they needed to make knowledgable decisions, and many seemed frustrated because of it.
Here's how the system works:
An applicant - a California researcher or university - applies to the stem cell institute for a grant. That application is reviewed by a working group of out-of-state scientists and eight patient advocates who serve on...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...